Jimenez Kylie 4
4 · BioNTech SE · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
BioNTech (BNTX) CPO Kylie Jimenez Receives Equity Awards
What Happened Kylie Jimenez, Chief People Officer of BioNTech SE, was granted two equity awards on 2026-05-12: 10,488 derivative units and 8,391 derivative units (total 18,879). Both were reported as awards/grants (code A) at $0.00 per unit — i.e., no cash was paid at grant. The awards consist of stock options and performance share units (PSUs) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-12; Form 4 filed 2026-05-13 (timely).
- Reported amounts: 10,488 and 8,391 derivative units; combined total 18,879.
- Price to insider at grant: $0.00 (award/grant). One option exercise price noted as EUR 89.38 (see footnote).
- Shares owned after the transaction: not specified in the provided excerpt.
- Footnotes (summary):
- Option exercise price: EUR 89.38; subject to adjustment so ADS trading price on exercise date does not exceed 800% of grant-date exercise price.
- Vesting: options and PSUs vest annually in equal installments over four years, starting one year after grant; exercisable/settleable after four years, subject to performance targets and continued service.
- Settlement: supervisory board may settle awards in ordinary shares, ADSs, and/or cash.
- PSUs: each PSU equals the economic value of one ordinary share, with payout tied to performance vs. the Nasdaq Biotechnology Index (or successor).
- Filing timeliness: filed the next day — not marked late.
Context These were compensation awards (stock options and performance share units) that require future vesting and, for PSUs, achievement of performance targets. Because they are derivative awards subject to multi-year vesting and potential performance conditions — and may be settled in shares, ADSs, or cash — they do not represent an immediate purchase or sale of stock and are not a direct bullish/sell signal. Executive awards are common as part of pay packages; monitor vesting dates and performance criteria for any eventual equity issuance or exercises.
Insider Transaction Report
- Award
Option (right to buy)
[F1][F2][F3]2026-05-12+10,488→ 10,488 totalFrom: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (10,488 underlying) - Award
Performance Share Unit
[F4]2026-05-12+8,391→ 8,391 totalExercise: $0.00From: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (8,391 underlying)
Footnotes (4)
- [F1]The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- [F2]The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- [F3]The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- [F4]Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.